CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of “Moderate Buy” by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $13.1667.

CVRX has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price target on shares of CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a research report on Thursday, October 30th. Finally, Cantor Fitzgerald boosted their target price on shares of CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th.

CVRx Stock Performance

CVRX stock opened at $9.36 on Thursday. The company has a quick ratio of 10.78, a current ratio of 11.99 and a debt-to-equity ratio of 0.85. The firm has a market cap of $245.35 million, a PE ratio of -4.46 and a beta of 1.28. The business has a 50 day moving average of $9.36 and a 200-day moving average of $7.89. CVRx has a 12-month low of $4.30 and a 12-month high of $18.55.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.01. The business had revenue of $14.69 million for the quarter, compared to analysts’ expectations of $14.16 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that CVRx will post -1.91 earnings per share for the current year.

Insiders Place Their Bets

In other CVRx news, major shareholder & Johnson Johnson sold 52,332 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $10.21, for a total transaction of $534,309.72. Following the completion of the transaction, the insider directly owned 4,051,098 shares of the company’s stock, valued at approximately $41,361,710.58. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 56,232 shares of company stock worth $573,442 over the last three months. 13.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Mount Lucas Management LP bought a new position in shares of CVRx during the 2nd quarter worth $30,000. Intech Investment Management LLC bought a new position in CVRx during the second quarter worth about $59,000. AlphaQuest LLC increased its stake in shares of CVRx by 725.4% in the first quarter. AlphaQuest LLC now owns 6,108 shares of the company’s stock worth $75,000 after purchasing an additional 5,368 shares in the last quarter. Philadelphia Trust Co. bought a new stake in shares of CVRx in the second quarter valued at approximately $88,000. Finally, Deutsche Bank AG lifted its stake in shares of CVRx by 41.5% during the 1st quarter. Deutsche Bank AG now owns 10,390 shares of the company’s stock valued at $127,000 after buying an additional 3,048 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.